RE:RE:RE:RE:Lung versus bladder? As we all know, when it comes to the dissemination of information to the market and shareholders Roger likes to be the centre of attention. Since firing his short time on the job PR duo this past spring he has taken on the chores of Investor Relations in addition to that of President, CEO and BOD member and probably adds his technical input to the device engineering side also. He is literally a one man band.
This company is betting heavily that enough positive efficacy indicators will surface after treating the first 3 patients to impress the market to the point of a least doubling the share price. As in the Motley Crew article that I posted a couple of days ago, the market will judge the credibility of the efficacy claims based on varying factors not the least of which is the size of the patient sampling and how strong the indicators are. To what degree efficacy claims will be seen as compelling to investors when only 3 patients are tested and observed for only a month remains to be seen but this in my view is one case where Roger should step aside and let the head of the cancer trial do the reporting. In my view it would have more of a market impact if the main hands on guy running the trial spoke in scientific terms on what they discovered rather than a CEO who might tend to exaggerate for the sake of convenience.
One other suggestion. Scrape the Korelin interview format and hold a shareholder conference call once every 3 months. It would be more informative for shareholders to have fund managers ask Roger questions live without giving him the opportunity to choose his words carefully ahead of time.
https://www.fool.com/investing/general/2014/04/21/biotech-investing-101-what-investors-need-to-know.aspx